These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

146 related items for PubMed ID: 16762554

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Synthesis and evaluation of novel 7-azaindazolyl-indolyl-maleimide derivatives as antitumor agents and protein kinase C inhibitors.
    Ye Q, Cao J, Zhou X, Lv D, He Q, Yang B, Hu Y.
    Bioorg Med Chem; 2009 Jul 01; 17(13):4763-72. PubMed ID: 19447039
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension.
    Zhu GD, Gandhi VB, Gong J, Thomas S, Woods KW, Song X, Li T, Diebold RB, Luo Y, Liu X, Guan R, Klinghofer V, Johnson EF, Bouska J, Olson A, Marsh KC, Stoll VS, Mamo M, Polakowski J, Campbell TJ, Martin RL, Gintant GA, Penning TD, Li Q, Rosenberg SH, Giranda VL.
    J Med Chem; 2007 Jun 28; 50(13):2990-3003. PubMed ID: 17523610
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Inhibitory action of protein kinase Cbeta inhibitor on tetrodotoxin-resistant Na+ current in small dorsal root ganglion neurons in diabetic rats.
    Hayase F, Matsuura H, Sanada M, Kitada-Hamada K, Omatsu-Kanbe M, Maeda K, Kashiwagi A, Yasuda H.
    Neurosci Lett; 2007 Apr 24; 417(1):90-4. PubMed ID: 17339081
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy.
    PKC-DRS2 GroupBeetham Eye Institute, Joslin Diabetes Center, 1 Joslin Place, Boston, MA 02215, USA. LPAiello@Joslin.Harvard.edu, Aiello LP, Davis MD, Girach A, Kles KA, Milton RC, Sheetz MJ, Vignati L, Zhi XE.
    Ophthalmology; 2006 Dec 24; 113(12):2221-30. PubMed ID: 16989901
    [Abstract] [Full Text] [Related]

  • 10. Acyclic N-(azacycloalkyl)bisindolylmaleimides: isozyme selective inhibitors of PKCbeta.
    Faul MM, Gillig JR, Jirousek MR, Ballas LM, Schotten T, Kahl A, Mohr M.
    Bioorg Med Chem Lett; 2003 Jun 02; 13(11):1857-9. PubMed ID: 12749884
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Design and synthesis of orally bioavailable benzimidazoles as Raf kinase inhibitors.
    Ramurthy S, Subramanian S, Aikawa M, Amiri P, Costales A, Dove J, Fong S, Jansen JM, Levine B, Ma S, McBride CM, Michaelian J, Pick T, Poon DJ, Girish S, Shafer CM, Stuart D, Sung L, Renhowe PA.
    J Med Chem; 2008 Nov 27; 51(22):7049-52. PubMed ID: 18942827
    [Abstract] [Full Text] [Related]

  • 13. Studies with an orally bioavailable alpha V integrin antagonist in animal models of ocular vasculopathy: retinal neovascularization in mice and retinal vascular permeability in diabetic rats.
    Santulli RJ, Kinney WA, Ghosh S, Decorte BL, Liu L, Tuman RW, Zhou Z, Huebert N, Bursell SE, Clermont AC, Grant MB, Shaw LC, Mousa SA, Galemmo RA, Johnson DL, Maryanoff BE, Damiano BP.
    J Pharmacol Exp Ther; 2008 Mar 27; 324(3):894-901. PubMed ID: 18083913
    [Abstract] [Full Text] [Related]

  • 14. 1-(2-Naphthyl)-1H-pyrazole-5-carboxylamides as potent factor Xa inhibitors. Part 3: Design, synthesis and SAR of orally bioavailable benzamidine-P4 inhibitors.
    Jia ZJ, Wu Y, Huang W, Zhang P, Song Y, Woolfrey J, Sinha U, Arfsten AE, Edwards ST, Hutchaleelaha A, Hollennbach SJ, Lambing JL, Scarborough RM, Zhu BY.
    Bioorg Med Chem Lett; 2004 Mar 08; 14(5):1229-34. PubMed ID: 14980671
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The Protein Kinase C Inhibitor: Ruboxistaurin.
    Deissler HL, Lang GE.
    Dev Ophthalmol; 2016 Mar 08; 55():295-301. PubMed ID: 26501476
    [Abstract] [Full Text] [Related]

  • 17. Discovery of potent and specific fructose-1,6-bisphosphatase inhibitors and a series of orally-bioavailable phosphoramidase-sensitive prodrugs for the treatment of type 2 diabetes.
    Dang Q, Kasibhatla SR, Reddy KR, Jiang T, Reddy MR, Potter SC, Fujitaki JM, van Poelje PD, Huang J, Lipscomb WN, Erion MD.
    J Am Chem Soc; 2007 Dec 19; 129(50):15491-502. PubMed ID: 18041834
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. 4-aminophenylalanine and 4-aminocyclohexylalanine derivatives as potent, selective, and orally bioavailable inhibitors of dipeptidyl peptidase IV.
    Duffy JL, Kirk BA, Wang L, Eiermann GJ, He H, Leiting B, Lyons KA, Patel RA, Patel SB, Petrov A, Scapin G, Wu JK, Thornberry NA, Weber AE.
    Bioorg Med Chem Lett; 2007 May 15; 17(10):2879-85. PubMed ID: 17350841
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.